Wide Ranks

GLPG

Galapagos NV

28.12

Top Statistics
Market Cap 1 B Forward PE -34.55 Revenue Growth -50.10 %
Current Ratio 10.13 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 79.33 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 10.83 Enterprise / Revenue -5.66 Price To Sales Trailing12 Months 7.12
Profitability
Profit Margins 79.33 % Operating Margins -90.74 %
Balance Sheet
Total Cash 3 B Total Cash Per Share 50.63 Total Debt 11 M
Total Debt To Equity 0.4010 Current Ratio 10.13 Book Value Per Share 43.41
All Measures
Short Ratio 594.00 % Message Board Id finmb_1716658 Fax 32 1 534 29 01
Shares Short Prior Month 1 M Return On Equity -0.0221 City Mechelen
Uuid 8ade642a-64d7-348a-ab37-8edc49ae1242 Previous Close 26.90 First Trade Date Epoch Utc 1 B
Book Value 43.41 Beta 0.0600 Total Debt 11 M
Volume 370782 Price To Book 0.6478 Fifty Two Week Low 24.16
Total Cash Per Share 50.63 Total Revenue 260 M Shares Short Previous Month Date 1 B
Target Median Price 28.01 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -90.74 % Target Mean Price 28.16 Net Income To Common -60611000
Short Percent Of Float 0.0306 Implied Shares Outstanding 66 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 391780 Average Volume10days 391780
Total Cash 3 B Next Fiscal Year End 1 B Revenue Per Share 0.1976
Ebitda Margins -52.30 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 26.90 Target Low Price 22.10
Gmt Off Set Milliseconds -18000000 Fifty Day Average 28.44 Open 27.24
Free Cashflow -283032736 Dividend Yield 0.00 % Return On Assets -0.0238
Time Zone Short Name EST Trailing Eps -0.9600 Day Low 27.24
Address1 Generaal De Wittelaan L11 A3 Shares Outstanding 65 M Price Hint 2
Target High Price 37.29 Website https://www.glpg.com 52 Week Change -0.2487
Average Volume 196940 Forward Eps -1.04 Recommendation Key none
Quick Ratio 975.40 % Is_sp_500 False Regular Market Day High 28.48
Profit Margins 79.33 % Debt To Equity 0.4010 Fifty Two Week High 42.46
Day High 28.48 Shares Short 1 M Regular Market Open 27.24
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue -5.66
Revenue Growth -50.10 % Shares Percent Shares Out 0.0228 Operating Cashflow -327523008
Currency USD Time Zone Full Name America/New_York Market Cap 1 B
Is_nasdaq_100 False Zip 2800 Quote Type EQUITY
Industry Biotechnology Long Name Galapagos NV Regular Market Day Low 27.24
Held Percent Institutions 0.3207 Current Price 28.12 Enterprise To Ebitda 10.83
Financial Currency EUR Current Ratio 10.13 Gross Margins -27.45 %
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country Belgium
Float Shares 44 M Two Hundred Day Average 29.06 Enterprise Value -1473011328
Price To Sales Trailing12 Months 7.12 Forward PE -34.55 Regular Market Volume 370782
Ebitda -136034752 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.

The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.

à r.

l.

Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.